AIDS · 2019 · 56 citations · 12 references
PharmacyPharmacokineticsPharmacotherapyHiv ControlHiv PreventionMolecular VirologyAntiretroviral TherapyAntiviral PharmacotherapyAntiviral TherapyHiv EpidemiologyWeight LossWeight ManagementAntiretroviral Therapy CoverageDolutegravir-based ProphylaxisHiv Antiretroviral TherapyIntegrase Strand Transfer InhibitorsMedian AgeNon-nucleoside Reverse Transcriptase InhibitorsNucleoside Reverse Transcriptase InhibitorsWeight Gain Velocity
OBJECTIVE: Excessive weight gain has been reported with integrase strand transfer inhibitors (INSTIs). We evaluated weight changes in virologically suppressed adults with HIV who switched from non-INSTI regimens to raltegravir (RAL)-containing or dolutegravir (DTG)-containing antiretroviral therapy. DESIGN: Retrospective single-centre cohort. METHODS: Adults who switched to RAL or DTG before or between January 2015 and October 2017 were identified. Virologically suppressed, treatment-experienced (≥2 years) individuals, at least 6 months on INSTI, with weight measurements 2 years or less pre and postswitch were included. Our analysis used a random effects model with linear slope pre and post-INSTI with adjustment for age, sex, ethnicity, preswitch-regimen (protease inhibitor vs. nonprotease inhibitor), and RAL vs. DTG use. RESULTS: A total of 378 individuals, 81.2% male, 70.1% white ethnicity, median age of 49 years, median of four weight measurements per participant, and median weight and BMI at switch of 76.6 kg and 25.3 kg/m, respectively, were included. Weight increased by an average of 0.63 kg/year (95% confidence interval 0.17-1.09) preswitch with no overall change in rate of weight gain postswitch [+0.05 kg/year (-0.61-0.71, P = 0.88)]. In our adjusted model, a transition from minimal weight change to weight gain postswitch was isolated to older individuals though this lacked statistical significance [e.g., +1.59 kg/year (-0.26-3.45) if aged 65 years]. Our findings did not differ by sex, ethnicity, preswitch regimen, or RAL vs. DTG. Similar results were seen for BMI and after adjusting for fixed nucleoside/nucleotide reverse transcriptase inhibitor backbone. CONCLUSION: We found no clear evidence of an overall increase in rate of weight gain following switch to INSTI in virologically suppressed individuals.
12
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Michael S. Saag, Constance A. Benson, Rajesh T. Gandhi et al. · JAMA · 2018 · 559 citations · Full text
Jamison Norwood, Megan Turner, Carmen Bofill et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2017 · 282 citations
M.J Mugavero, M.A. Thompson, C. Del Rio et al. · Kölner Universitäts PublikationsServer (Universität zu Köln) · 2020 · 205 citations · Full text